PMEL and melanoma: In an early phase I/II trial, patients with metastatic melanoma were treated intradermally with vaccines containing six melanoma antigens (MelanA, tyrosinase, gp100, MAGEA1/3, survivin), applying RNA protection with the cationic peptide protamin [96].